Background:We aimed to investigate the expression level of breast cancer susceptibility gene 2 (BRCA2) and its changes during chemotherapy in patients with different pathological types of mammary cancer (MC).
Methods:Overall, 102 patients treated in Affiliated Tumor Hospital of Guangxi Medical University, China from April 2013 to August 2017 were enrolled as experimental group, including 58 patients with noninvasive MC (group A) and 44 with invasive MC (group B). Fifty healthy volunteers at the same time were enrolled as control group. The relative expression of BRCA2 in the blood of MC patients was detected by real-time fluorescence quantitative PCR (FQ-PCR).
Results:In the experimental group, the expression level of BRCA2 in group A was higher than that in group B before chemotherapy (P<0.001); the expression level in group A and group B 1 month after chemotherapy was higher than that before chemotherapy (P<0.001); the expression level in the both groups 3 months after chemotherapy was higher than that 1 month after chemotherapy (P<0.001); the expression level of BRCA2 in blood of group A increased gradually before, 1 month and 3 months after chemotherapy (P<0.001). The expression level of BRCA2 in blood of group B increased gradually at the same time points (P<0.001).
Conclusion:BRCA2 is over-expressed in noninvasive MC patient and under-expressed in invasive MC patient. And it can be used as an index for monitoring the condition of MC patients with different pathological types during chemotherapy.
-
【The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer.].
【不同病理类型乳癌患者BRCA2的表达水平及其在化疗过程中的变化。】
复制标题
收藏
DOI：文章类型：杂志文章
复制DOI
译文
背景：我们的目的是研究乳腺癌的易感基因2（BRCA2）的表达水平及其在不同病理类型的乳腺癌（MC）患者化疗期间的变化。
方法：纳入2013年4月至2017年8月在广西医科大学附属肿瘤医院收治的102例患者作为实验组，其中58例为非侵入性MC（A组），44例为侵入性MC（B组）。同时纳入50名健康志愿者作为对照组。通过实时荧光定量PCR（FQ-PCR）检测MC患者血液中BRCA2的相对表达。
结果：实验组A组BRCA2表达高于化疗前B组（P <0.001）。 A组和B组化疗后1个月的表达水平高于化疗前（P <0.001）；两组化疗后3个月的表达水平均高于化疗后1个月（P <0.001）。 A组血液中BRCA2的表达在化疗前，化疗后1、3个月逐渐升高（P <0.001）。 B组血液中BRCA2的表达水平在同一时间点逐渐升高（P <0.001）。
结论：BRCA2在非侵袭性MC患者中过表达，而在侵袭性MC患者中过表达。可作为监测化疗过程中不同病理类型MC患者病情的指标。
方法：纳入2013年4月至2017年8月在广西医科大学附属肿瘤医院收治的102例患者作为实验组，其中58例为非侵入性MC（A组），44例为侵入性MC（B组）。同时纳入50名健康志愿者作为对照组。通过实时荧光定量PCR（FQ-PCR）检测MC患者血液中BRCA2的相对表达。
结果：实验组A组BRCA2表达高于化疗前B组（P <0.001）。 A组和B组化疗后1个月的表达水平高于化疗前（P <0.001）；两组化疗后3个月的表达水平均高于化疗后1个月（P <0.001）。 A组血液中BRCA2的表达在化疗前，化疗后1、3个月逐渐升高（P <0.001）。 B组血液中BRCA2的表达水平在同一时间点逐渐升高（P <0.001）。
结论：BRCA2在非侵袭性MC患者中过表达，而在侵袭性MC患者中过表达。可作为监测化疗过程中不同病理类型MC患者病情的指标。
